Scinovex
article Open AccessTop 1% cited

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

The Lancet · 2010 · Vol. 376(9742) · pp. 687–697
Yung‐Jue BangEric Van CutsemA. FeyereislovaHyun Cheol ChungLin ShenAkira SawakiFlorian LordickAtsushi OhtsuYasushi OmuroTaroh SatohGiuseppe AprileЕ. С. КуликовJulie HillMichaela LehleJosef RüschoffYoon‐Koo Kang
Gastric Cancer Management and OutcomesHER2/EGFR in Cancer ResearchGastrointestinal Tumor Research and TreatmentTrastuzumabMedicineInternal medicineCapecitabineChemotherapyRegimenCancerOncologyClinical endpointChemotherapy regimen

MeSH terms

TrastuzumabCapecitabineAdenocarcinomaAgedAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineDrug Therapy, CombinationEsophagogastric JunctionFemaleFluorouracilHumansMale
Citations
7,196
FWCI
237.39
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial · Scinovex